SPDR Portfolio Europe ETF
SPEU - ETF AI Analysis
Top Page
SPDR Portfolio Europe ETF (SPEU)
SPEU’s rating suggests it is a solid, but not top-tier, way to invest broadly in European companies. Strong holdings like Novartis, HSBC, and AstraZeneca, which show robust financial performance, positive earnings sentiment, and generally supportive valuations, help lift the fund’s overall quality. However, some holdings such as SAP and Shell face issues like bearish or weak technical trends, revenue and cash flow challenges, and valuation concerns, and the fund’s concentration in European markets is the main risk if that region underperforms.
SPEU vs. SPDR S&P 500 ETF (SPY)
- AUM
- 716.83M
- Region
- Europe
- Expense Ratio
- 0.07%
- Beta
- 0.72
- Issuer
- State Street
- Inception Date
- Oct 15, 2002
- Dividend Yield
- 3.52%
- Asset Class
- Equity
- Index Tracked
- STOXX Europe TMI
SPEU Summary
SPEU is the SPDR Portfolio Europe ETF, which follows the STOXX Europe TMI index. It gives you broad exposure to European stocks across many countries and industries in a single investment. The fund holds well-known companies like Nestlé, HSBC, Shell, and ASML, mixing large, established firms with smaller, growing businesses. Someone might invest in SPEU to diversify beyond the U.S. and tap into Europe’s long-term economic growth. A key risk is that the value of the ETF can go up and down with the European stock market and currency movements.
How much will it cost me?
This ETF has an expense ratio of 0.07%, which means you’ll pay about $0.70 per year for every $1,000 invested. That’s lower than average because it’s a passively managed fund that simply tracks a European stock market index instead of paying managers to pick individual stocks.
What would affect this ETF?
SPEU could benefit if Europe’s economy grows steadily, interest rates stabilize or fall, and demand stays strong for its major sectors like financials, health care, and energy, supporting companies such as ASML, Nestlé, and HSBC. On the downside, slower European growth, banking or energy sector stress, higher interest rates, or new regulations affecting big European firms could weigh on the ETF’s broad market holdings.
SPEU Top 10 Holdings
SPEU leans on a mix of European heavyweights, with ASML acting as a key engine for long‑term gains despite some recent wobbling, while energy names like Shell and TotalEnergies have been steadily powering the fund higher. On the defensive side, Roche and Novartis give the portfolio a solid healthcare backbone, both rising and helping smooth out volatility. Consumer giant Nestlé has been more mixed, losing a bit of steam lately, and AstraZeneca is lagging. Overall, the ETF is broadly diversified across developed Europe, rather than dominated by any single country or sector.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 3.60% | $25.71M | EUR 519.88B | 58.28% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NOVN | Novartis AG | 1.88% | $13.46M | CHF 246.17B | 27.54% | 80Outperform |
 GB:HSBA | HSBC Holdings | 1.87% | $13.40M | GBP 229.76B | 23.30% | 80Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 GB:SHEL | Shell (UK) | 1.64% | $11.71M | GBP 205.39B | 25.21% | 73Outperform |
 CH:NESN | Nestlé SA | 1.65% | $11.76M | CHF 222.27B | 5.72% | 71Outperform |
 DE:SAP | SAP SE | 1.44% | $10.29M | EUR 245.13B | -2.81% | 66Neutral |
 DE:SIE | Siemens | 1.36% | $9.70M | EUR 206.99B | 11.96% | 74Outperform |
 FR:TTE | TotalEnergies SE | 1.22% | $8.69M | EUR 174.56B | 43.42% | 78Outperform |
SPEU Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SPEU, the sentiment is Positive. The current price of 55.19 is above the 20-day moving average (MA) of 54.13, above the 50-day MA of 54.38, and above the 200-day MA of 53.91, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 57.40 is Neutral, neither overbought nor oversold. The STOCH value of 42.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SPEU.
SPEU Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| SPEU | $55.19 | $57.00(3.28% Upside) | $716.83M | 0.07% | 62Neutral |
 VGK | $89.46 | $104.14(16.41% Upside) | $30.30B | 0.06% | 61Neutral |
 IEUR | $76.00 | $88.02(15.81% Upside) | $9.81B | 0.09% | 63Neutral |
 DBEU | $55.81 | $64.64(15.82% Upside) | $800.60M | 0.46% | 64Neutral |
 GSEU | $49.21 | $58.06(17.99% Upside) | $173.88M | 0.25% | 62Neutral |
 FLEE | $38.99 | $45.64(17.05% Upside) | $101.18M | 0.09% | 63Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SPEU | SPDR Portfolio Europe ETF | 55.19 | 6.05 | 12.32% | |
| VGK | Vanguard FTSE Europe ETF | 89.46 | 10.20 | 12.87% | |
| IEUR | iShares Core MSCI Europe ETF | 76.00 | 8.51 | 12.60% | |
| DBEU | Xtrackers MSCI Europe Hedged Equity ETF | 55.81 | 8.73 | 18.55% | |
| GSEU | Goldman Sachs ActiveBeta Europe Equity ETF | 49.21 | 5.99 | 13.87% | |
| FLEE | Franklin FTSE Europe ETF | 38.99 | 4.34 | 12.51% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.